Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HGS Submits BLA For Interferon Zalbin For Hepatitis C

This article was originally published in The Pink Sheet Daily

Executive Summary

If approved, the interferon could offer a dosing advantage over pegylated interferons, although safety data could mean a bumpy regulatory road ahead.
Advertisement

Related Content

Novartis And HGS Close The Door On Zalbin
Novartis And HGS Close The Door On Zalbin
Merck And Vertex Poised For Growth In Singapore's HCV Market As Medical Tourism Booms
Novartis Boosts HCV Portfolio With First-in-Class Debiopharm Compound
Novartis Boosts HCV Portfolio With First-in-Class Debiopharm Compound
Benlysta Back In The Spotlight With BLISS-76, But Second Phase III Still May Not Be Enough To Support Some Claims
Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince
Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince
Albuferon Dosing Advantage: Less Is More For HCV Patients, Physicians Say

Topics

Advertisement
UsernamePublicRestriction

Register

PS068805

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel